REGN - Comprehensive Filing Intelligence

FYNone•10-K•Filed Feb 4, 2026
6.0/10
Filing Health:GOOD

Solid fundamentals with minor concerns to monitor

Executive Summary

Declining EYLEA sales due to competition and patient transition are a concern, though EYLEA HD is growing.. Sanofi collaboration revenue, driven by Dupixent, increased, offsetting some of the decline in product sales.. The company has a $750.0 million revolving credit facility, but no borrowings were outstanding as of December 31, 2025.. EYLEA HD revenue increased 36.3%

Top Concerns

  • !Declining EYLEA sales due to competition and patient transition are a concern, though EYLEA HD is growing.
  • !Sanofi collaboration revenue, driven by Dupixent, increased, offsetting some of the decline in product sales.
  • !Significant revenue decline in EYLEA (-$2.0B) due to competition and patient transition to EYLEA HD, but overall revenue only increased slightly ($0.14B) driven by collaboration revenue.
  • !Total provisions for rebates, chargebacks, and discounts increased significantly by $307.7M in 2025 compared to 2024, indicating potential pricing pressures or changes in sales terms.
  • !The company has a $750.0 million revolving credit facility, but no borrowings were outstanding as of December 31, 2025.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is confidently optimistic with focus on ongoing investments to support manufacturing operations.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows dependence on key products and reimbursement as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

6.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

BIIB 10-K Analysis: The $957M Earnings Gap Between Two Biogen Valuations

Analysis

REGN 10-K Analysis: Four Forces Manufacturing EPS Growth as Operations Decline